[Component in diphtheria-pertussis-tetanus-hepatitis B vaccine].
OBJECTIVE
To study immunogenecity of yeast-derived recombinant hepatitis B (YHB) component in diphtheria-pertussis-tetanus-YHB vaccine (DPTw-YHB).


METHODS
Immunogenecity of tetra-valent DTPw-YHB vaccine and mono-valent recombinant YHB vaccine, and that of the tetra-valent vaccine with varied YHB component were compared. The efficiency and stability of recombinant YHB in the tetra-valent vaccine stored at 2 - 8 degrees C for 18 months were determined.


RESULTS
The efficiency of recombinant YHB in the tetra-valent vaccine enhanced significantly in mice, as compared with that of mono-valent recombinant YHB vaccine, with an average mouse ED(50) of 1:2.0 - 1:3.1. There was no significant difference in efficiency of the tetra-valent vaccine with varied recombinant YHB component. Recombinant YHBin the DPTw-YHB tetra-valent vaccine still kept good stability stored at 2 - 8 degrees C for 18 months.


CONCLUSIONS
Recombinant YHB in the tetra-valent vaccine was more immunogenic than the mono-valent YHB vaccine. No interference and inhibition of DPTw to recombinant YHB was found, indicating good compatibility between DPTw and YHB.
Xie
D
D
National Vaccine and Serum Institute, Beijing 100024.
Zhang
J
J
Gong
Z
Z
Liu
B
B
Tang
Q
Q
Han
Y
Y
Dou
Y
Y
Zhao
J
J
D000818:Animals; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology*; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic